JP2003531157A5 - - Google Patents

Download PDF

Info

Publication number
JP2003531157A5
JP2003531157A5 JP2001577898A JP2001577898A JP2003531157A5 JP 2003531157 A5 JP2003531157 A5 JP 2003531157A5 JP 2001577898 A JP2001577898 A JP 2001577898A JP 2001577898 A JP2001577898 A JP 2001577898A JP 2003531157 A5 JP2003531157 A5 JP 2003531157A5
Authority
JP
Japan
Prior art keywords
present
pharmacology
medicine
fields
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001577898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/013135 external-priority patent/WO2001080796A1/en
Publication of JP2003531157A publication Critical patent/JP2003531157A/ja
Publication of JP2003531157A5 publication Critical patent/JP2003531157A5/ja
Pending legal-status Critical Current

Links

JP2001577898A 2000-04-26 2001-04-24 オキシブチニン治療に関連した有害な経験の最小化 Pending JP2003531157A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55971100A 2000-04-26 2000-04-26
US09/559,711 2000-04-26
PCT/US2001/013135 WO2001080796A1 (en) 2000-04-26 2001-04-24 Minimizing adverse experience associated with oxybutynin therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272243A Division JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化

Publications (2)

Publication Number Publication Date
JP2003531157A JP2003531157A (ja) 2003-10-21
JP2003531157A5 true JP2003531157A5 (https=) 2012-02-23

Family

ID=24234699

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001577898A Pending JP2003531157A (ja) 2000-04-26 2001-04-24 オキシブチニン治療に関連した有害な経験の最小化
JP2012272243A Expired - Lifetime JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化
JP2016160805A Expired - Lifetime JP6253734B2 (ja) 2000-04-26 2016-08-18 オキシブチニン治療に関連した有害な経験の最小化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012272243A Expired - Lifetime JP6077294B2 (ja) 2000-04-26 2012-12-13 オキシブチニン治療に関連した有害な経験の最小化
JP2016160805A Expired - Lifetime JP6253734B2 (ja) 2000-04-26 2016-08-18 オキシブチニン治療に関連した有害な経験の最小化

Country Status (15)

Country Link
US (6) US6743441B2 (https=)
EP (3) EP1280486B1 (https=)
JP (3) JP2003531157A (https=)
CN (4) CN101843601A (https=)
AT (1) ATE488233T1 (https=)
AU (2) AU2001253782B2 (https=)
BR (1) BR0110381A (https=)
CA (1) CA2406064C (https=)
CY (1) CY1111498T1 (https=)
DE (1) DE60143477D1 (https=)
DK (1) DK1280486T3 (https=)
ES (1) ES2357699T3 (https=)
MX (2) MX342305B (https=)
PT (1) PT1280486E (https=)
WO (1) WO2001080796A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN101843601A (zh) * 2000-04-26 2010-09-29 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US7276068B2 (en) 2002-10-04 2007-10-02 Sherwood Services Ag Vessel sealing instrument with electrical cutting mechanism
AU2012216593B2 (en) * 2002-11-01 2014-09-25 Allergan Sales, Llc Compositions and methods for transdermal oxybutynin therapy
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
JP5097359B2 (ja) 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3242659A4 (en) 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
CN110719778B (zh) 2017-04-24 2024-06-18 才思治疗公司 用于治疗抑郁的组合物和方法
EP3662905B1 (en) * 2017-08-01 2022-05-04 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US20240315971A1 (en) * 2023-03-03 2024-09-26 Lotus Biopharma Inc. Microsphere formulations and methods of preparation thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
NL124473C (https=) * 1960-07-26
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
EP0481007B1 (en) * 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA933349B (en) * 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
JP3688293B2 (ja) 1993-09-29 2005-08-24 アルザ・コーポレーション モノグリセリド／乳酸エステル透過促進剤
JP3021661B2 (ja) 1994-03-07 2000-03-15 セラテック・インコーポレーテッド 薬剤含有接着複合体の経皮放出デバイス
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
WO1996011022A1 (en) 1994-10-05 1996-04-18 Hisamitsu Pharmaceutical Co., Inc. DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-o-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5862555A (en) 1995-04-06 1999-01-26 Furuhashi; Masanobu System and method for manufacturing shoes using a wooden mold
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5769683A (en) * 1997-02-10 1998-06-23 Park; Young-Ho Attachment for balloon tether
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6479373B2 (en) * 1997-02-20 2002-11-12 Infineon Technologies Ag Method of structuring layers with a polysilicon layer and an overlying metal or metal silicide layer using a three step etching process with fluorine, chlorine, bromine containing gases
WO1998043611A1 (en) 1997-03-31 1998-10-08 Alza Corporation Diffusional implantable delivery system
KR20010006027A (ko) * 1997-04-03 2001-01-15 포인트 바이오메디칼 코퍼레이션 방광내 약물 송달 시스템
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
JP4139860B2 (ja) 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
DE29823343U1 (de) * 1998-03-20 1999-07-15 Schwarz Pharma Ag, 40789 Monheim Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
AR018321A1 (es) 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US5986305A (en) * 1998-03-30 1999-11-16 Texas Instruments - Acer Incorporated Semiconductor device with an inverse-T gate lightly-doped drain structure
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
CN101843601A (zh) * 2000-04-26 2010-09-29 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US6682368B2 (en) * 2000-05-31 2004-01-27 Tyco Electronics Corporation Electrical connector assembly utilizing multiple ground planes
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6662368B1 (en) * 2000-09-11 2003-12-09 Arris International, Inc. Variable spare circuit group size and quantity having multiple active circuits

Similar Documents

Publication Publication Date Title
JP2003531157A5 (https=)
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
SE0104340D0 (sv) New compounds
JP2003503454A5 (https=)
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
MXPA03011972A (es) Arilaminas para tratamiento de condiciones asociadas con gsk-3.
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
NO20053920D0 (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
DK1244435T5 (da) Polyhydroxylerede, aromatiske forbindelser til behandling af amyloidose og alpha-synuclein fibril sygdomme
JP2003520232A5 (https=)
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS6658A (is) Ný efnasambönd
JP2005237328A5 (https=)
JP2005504782A5 (https=)
JP2005509503A5 (https=)
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
SE0003476D0 (sv) Compounds
JP2004505922A5 (https=)
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
ATE399544T1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol